What Roivant Sciences does

Roivant Sciences Ltd. is a publicly traded (Nasdaq: ROIV) biopharmaceutical company founded in 2014 that develops and commercializes medicines and healthcare technologies through a portfolio of nimble, focused subsidiaries branded as "Vants." Active Vants include Immunovant (anti-FcRn antibodies batoclimab and IMVT-1402 for autoimmune indications), Priovant (brepocitinib, a dual TYK2/JAK1 inhibitor for dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris; in-licensed from Pfizer, which retains a 25% Priovant stake), Pulmovant (mosliciguat, an inhaled sGC activator licensed from Bayer for pulmonary hypertension associated with interstitial lung disease), Genevant Sciences (lipid nanoparticle drug delivery technology), Kinevant Sciences (namilumab for chronic pulmonary sarcoidosis), and Roivant Discovery (computational drug discovery built on the acquired Silicon Therapeutics platform). The portfolio historically also included Dermavant (VTAMA/tapinarof cream, divested to Organon for up to $1.2B in October 2024) and Telavant (RVT-3101, divested to Roche for $7.1B in October 2023), with the Genevant/Arbutus patent settlement against Moderna yielding $2.25B in March 2026.

Roivant's core technology stack centers on generative AI for proximity-based drug discovery: VantAI's Neo-1 foundation model (now operating as Proxima after an $80M seed round in January 2026) is described as the first model to simultaneously predict biomolecule structures and generate new molecular glues; PsiThera (spun out December 2025 with a $47.5M Series A) operates the QUAISAR physics-based simulation platform; and Lokavant provides clinical trial intelligence for protocol and enrollment optimization. The company reports 12 positive Phase 3 clinical trial readouts since 2019 and 8 FDA approvals across its portfolio.

Roivant monetizes through a hybrid model combining (i) outright subsidiary divestitures to large pharma (Roche, Organon), (ii) licensing and milestone economics on out-licensed assets and technology platforms (Bayer, BMS ~$674M, Blueprint ~$1.67B, Halda $1B, J&J multibillion-dollar Proxima collaboration, Epitopea up to $123.5M), (iii) patent litigation settlements (the $2.25B Moderna/Arbutus LNP settlement), and (iv) capital markets activity including $1.5B (2024) and $1B (2026) share repurchase programs alongside a Roivant-led $550M Immunovant financing in December 2025. The company is transitioning toward direct US commercialization of brepocitinib in dermatomyositis (expected end of September 2026, contingent on FDA Priority Review with a Q3 2026 PDUFA) while retaining a $4.3B cash position and a roughly $20.84B market capitalization, supported by a leadership team headed by CEO Matt Gline, President & CIO Mayukh Sukhatme, and Vant Chair Frank Torti.

Name

Roivant Sciences

Legal name

Roivant Sciences Ltd.

Website

https://roivant.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Roivant Sciences (Nasdaq: ROIV) is a biopharmaceutical company that develops and commercializes medicines and healthcare technologies through a portfolio of focused subsidiaries ("Vants"), with late-stage immunology assets (brepocitinib, IMVT-1402), an LNP delivery platform validated by a $2.25B Moderna settlement, and AI-driven drug-discovery platforms serving autoimmune and pulmonary disease patients.

Ownership category

akta.pro rank

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical product sales and royalties: Revenue generated from commercialization of proprietary drugs such as brepocitinib (autoimmune diseases including dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, lichen planopilaris, rheumatoid arthritis, Graves' disease, myasthenia gravis, CIDP, Sjögren's, thyroid eye disease) and IMVT-1402. Includes royalty streams from licensed products.
2. Subsidiary divestitures / asset sales: Outright divestitures of Roivant-owned subsidiaries to large pharma: Telavant sold to Roche for $7.1B (2023) and Dermavant/VTAMA sold to Organon for $1.2B. These are large, one-time transaction events that have historically driven significant cash inflows.
3. Licensing royalties and milestone payments: Recurring and milestone-based licensing revenue from out-licensed pipeline assets and platforms — including Bayer's licensing of mosliciguat to Pulmovant ($14M upfront, up to $280M milestones, total up to $294M), Genevant LNP license to Epitopea (up to $123.5M), and VantAI deals with Bristol Myers Squibb (~$674M) and Halda Therapeutics ($1B).
4. Patent settlement payments: Lump-sum payments arising from patent litigation settlements — most notably the $2.25B patent settlement with Moderna (jointly litigated with Arbutus Biopharma) involving Genevant's LNP technology.

Go-to-market motion4 records

Distribution channels4 records

Marketing channels6 records

Core offering

Roivant Sciences develops and commercializes biopharmaceutical medicines through a portfolio of focused, nimble subsidiaries called "Vants," each advancing drugs or technology platforms in specific therapeutic or technology areas. Its current pipeline includes brepocitinib (TYK2/JAK1 inhibitor) in autoimmune diseases, IMVT-1402 and batoclimab (FcRn inhibitors) in autoimmune diseases, mosliciguat (inhaled sGC activator) for pulmonary hypertension associated with interstitial lung disease, and namilumab for sarcoidosis, alongside drug delivery and AI discovery platforms such as Genevant LNP and Roivant Discovery.

Product overview

Roivant Sciences operates a hub-and-spoke biopharmaceutical platform that develops transformative medicines and technologies by building agile, focused subsidiaries called "Vants." The portfolio spans multiple therapeutic areas including immunology, dermatology, and pulmonary diseases through key subsidiaries: Immunovant (developing FcRn inhibitors batoclimab and IMVT-1402 for autoimmune diseases), Priovant (developing brepocitinib, a dual TYK2/JAK1 inhibitor, across dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris), Pulmovant (developing mosliciguat, an inhaled sGC activator for PH-ILD), and Genevant Sciences (lipid nanoparticle delivery technology platform). The model also includes technology platforms such as VantAI (now Proxima, AI-driven drug discovery), PsiThera (computational chemistry for inflammatory diseases), and Lokavant (clinical trial intelligence). Previously developed products include VTAMA (tapinarof cream for plaque psoriasis, sold to Organon in 2024) and RVT-3101/Telavant (anti-TL1A antibody sold to Roche for $7.1B in 2023).

Differentiator

Problem solved

Functional benefit

Brands

• Vant: Roivant's branded business model of building nimble, focused subsidiary companies (called "Vants") to develop and commercialize medicines and technologies. Used as a suffix in subsidiary names (e.g., Priovant, Pulmovant, Genevant).
• Roivant Discovery
• Roivant Health

Products and services

• Brepocitinib (Priovant) Dual TYK2/JAK1 inhibitor being developed for multiple autoimmune indications including dermatomyositis (NDA-stage with FDA Priority Review and Breakthrough Therapy Designation in cutaneous sarcoidosis), non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris; developed by Priovant Therapeutics, in which Pfizer holds a 25% equity stake.
• IMVT-1402 (Immunovant) Next-generation anti-FcRn monoclonal antibody being developed by Immunovant for multiple autoimmune indications including Graves' disease, myasthenia gravis, CIDP, Sjogren's syndrome, and rheumatoid arthritis.
• Batoclimab (Immunovant) Anti-FcRn monoclonal antibody developed by Immunovant for autoimmune indications including myasthenia gravis and thyroid eye disease.
• Mosliciguat (Pulmovant) Inhaled, once-daily soluble guanylate cyclase (sGC) activator in development for pulmonary hypertension associated with interstitial lung disease (PH-ILD), representing approximately 200,000 patients in the US and Europe. Phase 2 PHocus trial enrollment completed with topline data expected H2 2026.
• Namilumab (Kinevant Sciences) Anti-GM-CSF monoclonal antibody developed by Kinevant Sciences for chronic pulmonary sarcoidosis, with the RESOLVE-Lung Phase 2 study fully enrolled.
• Genevant Sciences LNP delivery platform Proprietary lipid nanoparticle (LNP) drug delivery technology for nucleic acid therapeutics, validated by the $2.25B Moderna patent settlement and licensed to Epitopea for RNA-based cancer immunotherapies.
• Roivant Discovery computational drug discovery platform Internal drug discovery platform led by CTO Huafeng Xu combining physics-based simulation methods, free energy calculations, structural immunology, and AI to advance Roivant's pipeline.

Quantifiable outcome

• 12 positive Phase 3 clinical trial readouts since 2019
• +4 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability9 records

Feature5 records

Partnerships

13 partnerships are on record, tiered flagship, major, core and minor.

• PfizerflagshipStrategic or Co-development PartnerRoivant in-licensed brepocitinib from Pfizer. Pfizer holds a 25% stake in Telavant (Roivant's subsidiary that was subsequently sold to Roche for $7.1B). RVT-3101 was in-licensed from Pfizer as well. Pfizer is a foundational pipeline source and a major transaction counterparty.
• RocheflagshipStrategic or Co-development PartnerIn December 2023, Roche acquired Roivant's subsidiary Telavant for $7.1B, one of the largest transactions in Roivant's history and the source of significant cash and recognition.
• OrganonmajorChannel Partner/ Reseller/ DistributorOrganon acquired Roivant's Dermavant subsidiary (including VTAMA/tapinarof cream) for $1.2B and assumed global commercial responsibility for the product.
• BayermajorStrategic or Co-development PartnerBayer licensed mosliciguat from Roivant's Pulmovant subsidiary for $14M upfront plus up to $280M in milestones (total deal up to $294M).
• Bristol Myers SquibbmajorStrategic or Co-development PartnerBMS entered into a partnership with Roivant's VantAI platform valued at approximately $674M for the discovery and development of molecular glues.
• Halda TherapeuticsmajorStrategic or Co-development PartnerVantAI entered a $1B RIPTAC (regulated induced proximity targeting chimera) partnership with Halda Therapeutics leveraging VantAI's generative AI capabilities.
• EpitopeacoreOEM/ Whitelabel/ Licensing PartnerEpitopea licensed Genevant's lipid nanoparticle (LNP) technology in a deal worth up to $123.5M in upfront and milestone payments.
• ModernaflagshipStrategic or Co-development PartnerRoivant (alongside Arbutus Biopharma) settled patent litigation with Moderna over LNP technology for $2.25B, validating Genevant's IP estate.
• Arbutus BiopharmacoreStrategic or Co-development PartnerCo-plaintiff with Roivant in the LNP patent litigation against Moderna that concluded in the $2.25B settlement.
• Sumitomo PharmamajorStrategic or Co-development PartnerSumitomo Pharma returned its stake to Roivant for $648M and subsequently entered a 2019 partnership with Roivant valued at $3B.
• AdimabminorStrategic or Co-development PartnerRoivant established a partnership with Adimab.
• Johnson & JohnsoncoreStrategic or Co-development PartnerJohnson & Johnson entered a research collaboration with Roivant's Proxima platform for proximity-based therapeutics.
• Blueprint MedicinescoreStrategic or Co-development PartnerBlueprint Medicines entered a research collaboration with Roivant's Proxima platform for proximity-based therapeutics.

Scale indicators11 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• BridgeBio Pharma: Closely comparable to Roivant's Vant model — BridgeBio operates multiple focused subsidiaries across rare disease therapeutic areas with a similar strategy of in-licensing and developing de-risked assets; both are public mid-cap biopharmacentric companies with subsidiary-driven structures.
• Arbutus Biopharma: Co-plaintiff with Roivant/Genevant in the $2.25B Moderna LNP patent settlement and itself focused on LNP delivery technology for nucleic acid therapeutics; directly comparable platform technology and litigation-driven revenue profile.
• Ultragenyx Pharmaceutical: Clinical-to-commercial stage rare disease biopharma with multiple late-stage programs and a focused pipeline approach; comparable in therapeutic area breadth (immunology/rare disease) and stage of transition from clinical to commercial.

Broad incumbents

• Vertex Pharmaceuticals: Established mid-to-large cap biopharma with similar innovation-driven R&D culture and significant cash reserves funding pipeline expansion; broader portfolio but operates in similar rare/specialty disease areas (CF, sickle cell) with comparable pipeline-to-launch execution capability.
• BioMarin Pharmaceutical: Established rare-disease focused biopharma with multiple approved products and ongoing late-stage pipeline development; comparable in therapeutic area focus (rare autoimmune/genetic) and capital allocation approach to specialized disease pipelines.
• Regeneron Pharmaceuticals: Major immunology-focused biopharma competing in autoimmune/inflammatory disease indications where brepocitinib and IMVT-1402 are targeted; broader Dupixent franchise directly competes with Roivant's immunology pipeline.

Emerging players

• Schrödinger: Computational drug discovery platform company comparable to Roivant Discovery / Silicon Therapeutics; both leverage physics-based computational methods and AI for small molecule discovery with similar biotech platform business models.
• Recursion Pharmaceuticals: AI-driven drug discovery platform comparable to Roivant's VantAI/Proxima platform; both apply machine learning to drug discovery and have multiple pharma partnerships; Recursion is more public-market focused as an AI biotech.
• Arvinas: Targeted protein degradation pioneer with PROTAC platform directly comparable to Roivant's Proxima proximity-based therapeutics platform; both pursue novel small-molecule degraders with pharma partnerships (BMS, Pfizer for Arvinas).
• Kymera Therapeutics: Molecular glue degrader platform comparable to VantAI/Proxima Neo-1 platform; both develop proximity-inducing small molecules for immunology and oncology indications with major pharma partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/roivant
• LinkedInlinkedin.com/company/roivant-sciences-inc-
• Facebookfacebook.com/Roivant

Revenue estimate

Valuation estimate

Number of profiles

Profiles22 records

Subsidiaries9 records

Funding overview

Funding rounds7 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roivant Sciences